Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG ($CRSP), made one open market purchase of shares in the last year, totaling nearly $50,000, with the most recent on April 3, 2025. This ranks 3,043rd among 4,983 insiders, well below the average $1.5 million across 3.3 transactions. He also sold shares once for $141,000, most recently on May 29, 2025, ranking 9,068th out of 11,678 insiders versus the typical $8.6 million over 6.4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2026 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Stock Option (Right to Buy) | 38499 | $0.00 | 38,499.0000 | 95,985,312 | 9999.99% | 0.04% |
| March 20, 2026 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Restricted Stock Units | 30000 | $0.00 | 30,000.0000 | 95,985,312 | 9999.99% | 0.03% |
| March 16, 2026 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | S | Common Shares | 3150 | $48.26 | 13,143.0000 | 95,985,312 | 19.33% | 0.00% |
| March 14, 2026 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | M | Restricted Stock Units | 8125 | $0.00 | 24,375.0000 | 95,985,312 | 25.00% | 0.01% |
| March 14, 2026 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | M | Common Shares | 8125 | $0.00 | 16,293.0000 | 95,985,312 | 99.47% | 0.01% |
| April 3, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | P | Common Shares | 1508 | $32.96 | 1,508.0000 | 85,774,474 | 9999.99% | 0.00% |
| Oct. 3, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Stock Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 85,774,474 | 9999.99% | 0.02% |
| May 30, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Restricted Stock Units | 25000 | $0.00 | 25,000.0000 | 85,774,474 | 9999.99% | 0.03% |
| May 28, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | M | Restricted Stock Units | 10000 | $0.00 | 30,000.0000 | 85,774,474 | 25.00% | 0.01% |
| May 29, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | S | Common Shares | 3932 | $35.94 | 6,068.0000 | 85,774,474 | 39.32% | 0.00% |
| May 28, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | M | Common Shares | 10000 | $0.00 | 10,000.0000 | 85,774,474 | 9999.99% | 0.01% |
| March 14, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Restricted Stock Units | 32500 | $0.00 | 32,500.0000 | 85,774,474 | 9999.99% | 0.04% |
| March 14, 2025 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Stock Option (Right to Buy) | 46667 | $0.00 | 46,667.0000 | 85,774,474 | 9999.99% | 0.05% |
| Oct. 16, 2024 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Stock Option (Right to Buy) | 18333 | $0.00 | 18,333.0000 | 0 | 9999.99% | 0.00% |
| May 28, 2024 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Restricted Stock Units | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| May 28, 2024 | CRISPR Therapeutics AG | $CRSP | Patel Naimish | Chief Medical Officer | A | Stock Option (Right to Buy) | 85000 | $0.00 | 85,000.0000 | 0 | 9999.99% | 0.00% |